Alnylam Pharmaceuticals
ALNY
ALNY
315 hedge funds and large institutions have $12.3B invested in Alnylam Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 72 funds opening new positions, 98 increasing their positions, 98 reducing their positions, and 29 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
315
Holders Change
+35
Holders Change %
+12.5%
% of All Funds
6.22%
Holding in Top 10
12
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+9.09%
% of All Funds
0.24%
New
72
Increased
98
Reduced
98
Closed
29
Calls
$155M
Puts
$139M
Net Calls
+$15.3M
Net Calls Change
-$18.3M
Top Buyers
| 1 |
1
BlackRock
New York
|
$925M |
| 2 |
2
T. Rowe Price Associates
Baltimore,
Maryland
|
$616M |
| 3 |
AG
3
Artal Group
Luxembourg
|
$115M |
| 4 |
SPC
4
Slate Path Capital
New York
|
$93.9M |
| 5 |
5
Federated Hermes
Pittsburgh,
Pennsylvania
|
$84.6M |
Top Sellers
| 1 |
MC
1
Maverick Capital
Dallas,
Texas
|
$260M |
| 2 |
FAM
2
Fred Alger Management
New York
|
$2.65M |
| 3 |
3
Wellington Management Group
Boston,
Massachusetts
|
$1.65B |
| 4 |
4
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
$32.4M |
| 5 |
5
Goldman Sachs
New York
|
$96.5M |
